Increasing evidence points to DGKα as a critical node in oncogenic signaling and as a putative novel therapeutic target in cancer: inhibition or silencing of DGKα has been shown to reduce tumor growth and mortality in glioblastoma and hepatic carcinoma xenograft models [13], [14]. This evidence concerns the gene DGKA and cancer.